Follow this innovation
[ via 
] [?]
Peptide Conjugates for Imaging and Treating Pancreatic Cancer
University of California System: University of California, Davis - UC Davis
posted on 06/18/2009
Radiolabeled PEGylated peptide radiotracer for detection of integrin alpha-v beta-6 in vitro and in vivo
Suggested Uses
Positron emission tomography (PET) imaging of αvß6--expression in tumors for detection of often-overlooked cancers (e.g., pancreatic cancer).
Advantages
- May serve as a diagnostic and prognostic indicator of disease in a noninvasive manner
- May lead to the development of other imaging probes and targets
Detailed Description
Researchers at the University of California, Davis have developed a method for the convenient synthesis and improved in vivo behavior of a probe for targeted in vivo and in vitro detection of the integrin alpha-v beta-6 (αvß6), a cell surface receptor linked to certain cancers. Using this method, UC Davis researchers have identified pancreatic cancer as a novel target for imaging αvß6-expression in vivo and successfully imaged a mouse model by PET. Tumors not detected by standard imaging probes were clearly visualized by these peptide conjugates. Additionally, the peptide conjugates developed by this method are fully compatible with standard peptide and radiolabeling chemistries, thus making the approach widely employable.
Positron emission tomography (PET) transaxial images of pancreatic cancer model in a mouse. The alpha-v beta-6 targeting peptide conjugate clearly revealed the tumor.
File Number: 19162
Disease: Cancer
| Copyright: | ©2009-2010, The Regents of the University of California |
|---|
This innovation currently is not available for online licensing. Please contact Nancy Rashid at University of California System: University of California, Davis - UC Davis for more information.
request more info
ProfileFind more innovations
